Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesPRNewsWire • 03/21/24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityPRNewsWire • 03/12/24
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 03/12/24
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 01/02/24
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferencePRNewsWire • 11/22/23
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesPRNewsWire • 11/09/23
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 11/02/23
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 10/19/23
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 09/20/23
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 09/13/23
Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesPRNewsWire • 09/05/23
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent UpdatesPRNewsWire • 08/08/23
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferencePRNewsWire • 08/02/23
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney ConferencePRNewsWire • 07/18/23
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 06/27/23
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's HospitalPRNewsWire • 06/20/23
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 05/16/23
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent UpdatesPRNewsWire • 05/11/23